Abstract 13439: Detection of Atrial Fibrillation With a Portable Device During Cardiovascular Disease Screening in Primary Care: Data From the PROVAR + Study

• Published in: Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A13439-A13439
• Main Authors: Diamantino, Adriana C, Nascimento, Bruno R, Beaton, Andrea Z, Nunes, Maria Do Carmo P, Oliveira, Kaciane K, Rabelo, Lara C, Barbosa, Marcia, Reese, Alison T, Olivieri, Laura, Mata, Mariana D, Rios, João Pedro P, Pereira, Augusto F, Diamantino, Luciana C, Ribeiro, Antonio L, Sable, Craig A, Brant, Luisa C
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.140.suppl_1.13439

IntroductionAtrial fibrillation (AF) is the most common arrhythmia and is associated with significant morbidity. Portable devices such as MyDiagnostick® (MDS) allow for AF screening. We aimed to evaluate the sensitivity and specificity of MDS for AF diagnosis in patients in the waiting list for echocardiogram (ECHO) in primary care and to assess the prevalence of AF by this method.MethodsIn 5 days, 1,518 patients from low-income areas of Brazil underwent clinical evaluation and cardiovascular (CV) risk stratification using a study-derived score based on demographics and CV comorbidities. Patients were then screened for AF with MDS, holding the device with both hands for 1-minute. The test was considered positive when the device indicated the presence of AF. The gold-standard for AF diagnosis was the 12-lead ECG interpreted by a cardiologist. Patients with intermediate CV risk were submitted to ECHO screening with ultraportable device. Individuals with abnormalities in screening or those with high CV risk, in addition to a low-risk sample, underwent standard ECHO. Major heart disease (HD) was defined as moderate to severe valve disease, ventricular dysfunction/hypertrophy, pericardial effusion or wall-motion abnormalities.ResultsMean age was 58 ± 16 years, 66% were women. Prevalence of AF by MDS was 6.4% (N=97)higher in patients with high CV risk (12.6%), compared with moderate (6.1%) and low risk (2.2 %), p65-year-olds (9.3%) than in those aged 40-64 years (4.2%) and